BioNTech SE (NASDAQ:BNTX) is one of the best healthcare stocks to buy with highest upside potential. BioNTech SE (NASDAQ:BNTX ...

BioNTech (BNTX) is back in focus after recent trading left the stock at a last close of US$88.08, with investors weighing its cancer and infectious disease pipeline against current revenue and ...

BioNTech sails into ASCO with two clinical readouts that underscore its pivot toward oncology beyond vaccines, even as the stock trades under mid-year pressure and investors weigh the pace of the ...

Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to ...

Start a conversation with TipRanks’ trusted, data-backed investment intelligence Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds An update from ...

BioNTech SE has agreed to acquire British artificial intelligence (AI) startup InstaDeep for up to 562 million pounds ($682 ...

The company’s financial buffer remains formidable: €16.76 billion in cash and marketable securities. Yet even as BioNTech pours money into its cancer programs, it is simultaneously slimming down its ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

BioNTech, a biotech company best known for its successful development of a messenger RNA Covid-19 vaccine, is acquiring fellow mRNA company CureVac in a $1.25 billion stock deal that brings together ...

BioNTech SE (NASDAQ: BNTX) and Bristol Myers Squibb & Co. (NYSE: BMY) on Tuesday shared the first interim data from a global randomized Phase 2 trial of pumitamig (BNT327/BMS986545) plus chemotherapy ...